A statement released earlier today by Iberia Capital about Energy Recovery (NASDAQ:ERII) bumps the target price to $21.00
- Updated: September 27, 2016
Iberia Capital bumped up the target of Energy Recovery (NASDAQ:ERII) to $21.00 stating a potential upside of 0.31%.
On Monday September 26, 2016, Iberia Capital released a statement for Energy Recovery (NASDAQ:ERII) bumped up the target price from $0.00 to $21.00 that suggested an upside of 0.36%.
Boasting a price of $16.06, Energy Recovery (NASDAQ:ERII) traded 6.24% higher on the day. With the last stock price close up 45.73% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Energy Recovery has recorded a 50-day average of $13.24 and a two hundred day average of $11.10. Volume of trade was down over the average, with 430,526 shares of ERII changing hands under the typical 542,953
With a total market value of $0, Energy Recovery has with a one year low of $2.07 and a one year high of $16.49 .
Brief Synopsis About Energy Recovery (NASDAQ:ERII)
Energy Recovery, Inc. is an energy solutions provider to industrial fluid flow markets. The Company's solutions convert wasted pressure energy into a reusable asset and preserve or eliminate pumping technology in hostile processing environments. It operates through two segments: Water, and Oil & Gas. Its Water Segment focuses on products sold for use in reverse osmosis water desalination. Its Oil & Gas Segment consists of products sold for use in gas processing, chemical processing, and hydraulic fracturing. It offers energy recovery devices (ERDs) in the water desalination market with its pressure exchanger technology and turbochargers. It offers VorTeq hydraulic fracturing system (VorTeq), IsoBoost, and IsoGen product lines to the oil and gas market. Its solutions are marketed and sold in fluid flow markets, such as water, oil and gas, and chemical processing, under the trademarks ERI, PX, Pressure Exchanger, PX Pressure Exchanger, AT, AquaBold, VorTeq, IsoBoost, and IsoGen.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.